首頁 > 市場調查報告書 > 製藥

癌症呼吸器

市場調查報告書

商品編碼

2055042

肺癌市場：按類型、藥物類別、分子類型、給藥途徑、疾病階段、年齡層、性別、分銷管道、最終用戶和地區分類。

Lung Cancer Market, By Type, By Drug Class, By Molecule Type, By Route of Administration, By Stage of Disease, By Age Group, By Gender, By Distribution Channel, By End User, By Geography

出版日期: 2026年03月10日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，肺癌市場在2026年的價值為317.2億美元，預計到2033年將達到737億美元。預計從2026年到2033年，其複合年成長率將達到12.8%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	317.2億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	12.80%	2033年市場規模預測：	737億美元

全球肺癌市場是癌症治療領域最重要的細分市場之一，其成長動力主要源自於肺癌這一持續存在的挑戰，而肺癌是全球癌症相關死亡的主要原因之一。這種惡性腫瘤每年影響數百萬患者，其中非小細胞肺癌（NSCLC）約佔所有病例的85%，小細胞肺癌（SCLC）約佔15%。該市場治療性介入，包括化療、標靶治療、免疫療法、放射線治療和外科手術，以及診斷工具和支持性護理解決方案。

吸煙、環境污染、職業風險因素和遺傳易感性等因素導致的疾病發病率不斷上升，持續推動全球需求。在治療領域，精準醫療方法的引入取得了突破性進展，例如基於生物標記的療法、免疫查核點抑制劑和蛋白酪氨酸激酶抑制劑，顯著改善了患者的治療效果。醫療基礎設施的改善、早期檢測項目意識的提高以及製藥公司在研發方面的大量投入，正在重塑市場格局。

市場動態

全球肺癌市場受多種市場促進因素推動，呈現強勁成長勢頭，但同時也面臨一些限制其擴張的因素。然而，這些因素也為未來的發展提供了巨大的機會。主要市場促進因素包括全球肺癌發生率的上升，而這又歸因於菸草消費量的增加、空氣污染、職業性致癌性暴露以及遺傳易感性，這些因素共同導致需要治療性介入的患者群體不斷擴大。

免疫療法的突破性進展，特別是免疫查核點抑制劑（如PD-1/PD-L1抑制劑）的研發，徹底改變了治療模式，並創造了巨大的市場機會。同時，針對特定基因突變（如EGFR、ALK和ROS1）的標靶治療的開發，使得個人化治療方案得以實現，並顯著提高了療效。新興國家醫療基礎設施的改善，加上醫療成本的上升以及篩檢計畫對早期診斷意識的提高，進一步加速了市場成長。

然而，市場擴張面臨諸多限制，包括創新癌症療法成本極高，限制了其可及性，尤其是在發展中地區；嚴格的法規結構延長了藥物核准流程；以及藥物研發過程的複雜性，儘管結果不確定，但仍需要大量投資。

專利到期給現有公司帶來了價格壓力和市場佔有率下降。然而，透過開發聯合治療以提高治療效果、進入尚未開發的區域市場、推進個人化醫療的伴隨診斷以及整合人工智慧 (AI) 和機器學習技術以改進診斷和治療方法方案，仍然存在著巨大的機會。對早期癌症治療的日益重視、新型藥物遞送系統的開發以及製藥公司與研究機構之間合作的加強，都預示著市場擴張和創新還有更多途徑。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數創建了全球肺癌市場主要公司的概況：公司亮點、產品系列、主要特徵、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球肺癌市場報告的目標受群眾外包括產業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過用於分析全球肺癌市場的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第14章競爭格局

Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca plc
Bristol Myers Squibb Company
Merck and Co., Inc.（MSD）
Pfizer Inc.
Eli Lilly and Company
Johnson and Johnson（Janssen Biotech, Inc.）
Amgen Inc.
AbbVie Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company, Limited
Astellas Pharma Inc.
Regeneron Pharmaceuticals, Inc.

第15章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第16章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI8494

Lung Cancer Market is estimated to be valued at USD 31.72 Bn in 2026 and is expected to reach USD 73.70 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 31.72 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	12.80%	2033 Value Projection:	USD 73.70 Bn

The global lung cancer market represents one of the most critical segments within the oncology therapeutics landscape, driven by the persistent challenge of lung cancer as the leading cause of cancer-related mortality worldwide. This malignancy affects millions of patients annually, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases, while small cell lung cancer (SCLC) comprises the remaining 15%. The market encompasses a comprehensive spectrum of therapeutic interventions including chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures, alongside diagnostic tools and supportive care solutions.

Rising prevalence rates attributed to smoking habits, environmental pollutants, occupational hazards, and genetic predispositions continue to fuel demand globally. The therapeutic landscape has witnessed revolutionary advancements through the introduction of precision medicine approaches, including biomarker-driven treatments, immune checkpoint inhibitors, and tyrosine kinase inhibitors that have significantly improved patient outcomes. Healthcare infrastructure development, increasing awareness about early detection programs, and substantial investments in research and development activities by pharmaceutical companies are collectively shaping the market trajectory.

Market Dynamics

The global lung cancer market is propelled by multiple driving factors that collectively contribute to its robust growth trajectory, while simultaneously facing certain constraints that moderate expansion rates, yet presenting significant opportunities for future development. Primary market drivers include the escalating global incidence of lung cancer due to increasing tobacco consumption, air pollution, occupational exposure to carcinogens, and genetic susceptibilities, which collectively expand the patient population requiring therapeutic interventions.

The revolutionary advancement in immunotherapy treatments, particularly immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors, has transformed treatment paradigms and created substantial market opportunities, while targeted therapy developments focusing on specific genetic mutations like EGFR, ALK, and ROS1 have enabled personalized treatment approaches that demonstrate superior efficacy rates. Healthcare infrastructure improvements in emerging economies, coupled with increasing healthcare expenditure and growing awareness about early diagnosis through screening programs, further accelerate the market growth.

However, market expansion faces significant restraints including the extremely high costs associated with innovative cancer treatments, which limit accessibility particularly in developing regions, stringent regulatory frameworks that prolong drug approval timelines, and the complex nature of drug development processes that require substantial investments with uncertain outcomes.

Patent expiration of blockbuster drugs creates pricing pressures and market share erosion for established players. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance treatment efficacy, expansion into untapped geographical markets, advancement in companion diagnostics for personalized medicine, and the integration of artificial intelligence and machine learning technologies for improved diagnosis and treatment selection. The growing focus on early-stage cancer treatment, development of novel drug delivery systems, and increasing collaborations between pharmaceutical companies and research institutions present additional avenues for market expansion and innovation.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca plc, Bristol Myers Squibb Company, Merck and Co., Inc. (MSD), Pfizer Inc., Eli Lilly and Company, Johnson and Johnson (Janssen Biotech, Inc.), Amgen Inc., AbbVie Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Astellas Pharma Inc., and Regeneron Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lung cancer market.

Market Segmentation

Type Insights (Revenue, USD Bn, 2021 - 2033)
Non-Small Cell Lung Cancer (NSCLC)
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
Small Cell Lung Cancer (SCLC)
Lung Carcinoid Tumor
Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
Cytotoxic Chemotherapy
- Alkylating agents (cisplatin, carboplatin, etc.)
- Antimetabolites (pemetrexed, gemcitabine)
- Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
- Topoisomerase inhibitors (etoposide, irinotecan)
- Others
Targeted Therapy
- EGFR Inhibitors (Erlotinib, etc.)
- ALK Inhibitors (Crizotinib, etc.)
- ROS1 Inhibitors (Entrectinib, etc.)
- BRAF/MEK Inhibitors (Dabrafenib, etc.)
- MET Inhibitors (Capmatinib, etc.)
- RET Inhibitors (Selpercatinib, etc.)
- HER2 Inhibitors (Trastuzumab, etc.)
Immunotherapy
- PD-1 Inhibitors (Nivolumab, etc.)
- PD-L1 Inhibitors (Atezolizumab, etc.)
- CTLA-4 Inhibitors (Ipilimumab, etc.)
Other Combination Therapeutics
Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)
Small Molecules
Biologics
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
Parenteral
Oral
Stage of Disease Insights (Revenue, USD Bn, 2021 - 2033)
Early-stage (Stage I-II)
Locally Advanced (Stage III)
Metastatic/Advanced (Stage IV)
Age Group Insights (Revenue, USD Bn, 2021 - 2033)
Adult
Pediatric
Geriatric
Gender Insights (Revenue, USD Bn, 2021 - 2033)
Male
Female
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
End User Insights (Revenue, USD Bn, 2021 - 2033)
Hospitals
Diagnostic Laboratories
Specialty Cancer Clinics
Homecare Settings
Others (Research and Academic Institutes, etc.)
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca plc
Bristol Myers Squibb Company
Merck and Co., Inc. (MSD)
Pfizer Inc.
Eli Lilly and Company
Johnson and Johnson (Janssen Biotech, Inc.)
Amgen Inc.
AbbVie Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company, Limited
Astellas Pharma Inc.
Regeneron Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Lung Cancer Market, By Type
- Global Lung Cancer Market, By Drug Class
- Global Lung Cancer Market, By Molecule Type
- Global Lung Cancer Market, By Route of Administration
- Global Lung Cancer Market, By Stage of Disease
- Global Lung Cancer Market, By Age Group
- Global Lung Cancer Market, By Gender
- Global Lung Cancer Market, By Distribution Channel
- Global Lung Cancer Market, By End User
- Global Lung Cancer Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Lung Cancer Market, By Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Non-Small Cell Lung Cancer (NSCLC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Adenocarcinoma
  - Squamous Cell Carcinoma
  - Large Cell Carcinoma
Small Cell Lung Cancer (SCLC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Lung Carcinoid Tumor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Lung Cancer Market, By Drug Class, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cytotoxic Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Alkylating agents (cisplatin, carboplatin, etc.)
  - Antimetabolites (pemetrexed, gemcitabine)
  - Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
  - Topoisomerase inhibitors (etoposide, irinotecan)
  - Others
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - EGFR Inhibitors (Erlotinib, etc.)
  - ALK Inhibitors (Crizotinib, etc.)
  - ROS1 Inhibitors (Entrectinib, etc.)
  - BRAF/MEK Inhibitors (Dabrafenib, etc.)
  - MET Inhibitors (Capmatinib, etc.)
  - RET Inhibitors (Selpercatinib, etc.)
  - HER2 Inhibitors (Trastuzumab, etc.)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - PD-1 Inhibitors (Nivolumab, etc.)
  - PD-L1 Inhibitors (Atezolizumab, etc.)
  - CTLA-4 Inhibitors (Ipilimumab, etc.)
Other Combination Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Lung Cancer Market, By Molecule Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Lung Cancer Market, By Route of Administration, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Lung Cancer Market, By Stage of Disease, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Early-stage (Stage I-II)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Locally Advanced (Stage III)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Metastatic/Advanced (Stage IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Lung Cancer Market, By Age Group, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Lung Cancer Market, By Gender, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

11. Global Lung Cancer Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

12. Global Lung Cancer Market, By End User, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Specialty Cancer Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others (Research and Academic Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

13. Global Lung Cancer Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

14. Competitive Landscape

Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck and Co., Inc. (MSD)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson and Johnson (Janssen Biotech, Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies